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GUEST EDITORIAL
Chemotherapy for advanced bladder cancer: 'Midsummer Night's Dream'
or 'Much Ado About Nothing'?
D. Raghavan
Urological Cancer Research Unit and Department ofClinical Oncology, Royal Prince Alfred Hospital, Sydney, Australia.
The past decade has seen important progress in our under-
standing of the biology and management of bladder cancer,
one of the most common malignancies in Western society.
Important concepts have emerged regarding the functional
heterogeneity of bladder tumours that appear similar under
the light microscope, but which are composed of subpopula-
tions of cells with different metastatic and invasive properties
(Brown et al., 1990). Extensive data have been produced with
regard to newer and more accurate indices of prognosis,
including the expression of epidermal growth factor receptor,
DNA content, marker chromosomes and the expression of
oncogenes, as reviewed in detail elsewhere (Raghavan et al.,
1990).
However, it has become increasingly clear that, despite the
best available treatment, approximately 50 per cent of
patients presenting with invasive transitional cell carcinoma
will die within 5 years (Skinner & Lieskovsky, 1984; Gospo-
darowicz et al., 1989). The traditional determinants of
adverse prognosis include advanced tumour stage, size, high
grade, and the presence of hydronephrosis (Shipley et al.,
1984; Gospodarowicz et al., 1989), and studies are in pro-
gress to determine the relative utility of these factors, com-
pared to the more recently introduced determinants listed
above.
Patients with loco-regional recurrence or distant metastases
have been treated with systemic cytotoxics, occasionally
achieving dramatic remissions. As a result, patients with
invasive, but clinically non-metastatic bladder cancer have
more recently been treated with initial systemic chemother-
apy as part of planned definitive treatment in an attempt to
improve cure rates. Although there have been many early
reports of high response rates, it has not been clear whether
real progress has been made with improvement in survival.
Thus it is timely to discuss the available data regarding the
use of chemotherapy for locally advanced, recurrent and
metastatic bladder cancer.
Chemotherapy for metastatic and recurrent bladder cancer
For more than 30 years, cytotoxic chemotherapy has under-
gone evaluation in the management of bladder cancer (Wil-
son, 1960; Carter & Wasserman, 1975; Young & Garnick,
1988; Tonkin & Tannock, 1988). The data from the early
phase clinical trials have reflected the criteria of assessment
of outcome and the techniques of supportive care as they
have evolved. Thus, for any cytotoxic drug or combination
of drugs, a broad range of response rates and levels of
toxicity have been reported. When criteria of assessment that
would have been acceptable by current standards (Van
Oosterom et al., 1986; Tonking & Tannock, 1988) have been
used, it has been clear that objective response rates of 20-35
per cent can be achieved in metastatic or recurrent bladder,
or urothelial tract tumours treated with cisplatin, doxorub-
icin, methotrexate, mitomycin or cyclophosphamide, used as
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single agents (Young & Garnick, 1988; Tonkin & Tannock,
1988). When such drugs have been used in this fashion in
typical elderly patients with bladder cancer, the toxicity has
been manageable, with nausea and mild-to-moderate myelo-
suppression being the predominant features.
Since 1977, many uncontrolled trials have yielded high
objective response rates and a broad range of toxicity when
combination chemotherapy regimens have been applied to
this problem. Whether high objective response rates actually
translate into a survival benefit has not been addressed in
these trials. However, single agent chemotherapy has been
compared with combination regimens in several randomised
trials (Table I), most of which have failed to reveal a statis-
tically significant or clinically relevant survival benefit from
combination chemotherapy. Moreover, in these trials, com-
bination regimens have caused significantly greater levels of
toxicity (Soloway et al., 1983; Khandekar et al., 1985; Troner
et al., 1987; Hillcoat et al., 1989). Despite the lack of evi-
dence supporting the use of combination regimens, investi-
gators have continued to develop more intricate (and toxic)
regimens, predicated on the hope that high response rates
would ultimately translate into improved survival. Of partic-
ular importance are two studies with clearly defined criteria
of response and toxicity, in which the combination of metho-
trexate, cisplatin and vinblastine (with or without doxo-
rubicin) - the CMV or MVAC regimens - have yielded
reproducibly high response rates in primary tumours and in
metastatic deposits (Meyers et al., 1985; Sternberg et al.,
1985, 1988). Complete responses proved by biopsy have been
noted in liver, bones, lungs, lymph nodes and soft tissue
deposits (Sternberg et al., 1988). Regrettably, the separate
reporting of survival for responding and non-responding
patients (Sternberg et al., 1988) initially created the illusion
that the problem of metastatic bladder cancer may have been
solved (Olsson, 1987). However, with increased experience
(Tannock et al., 1989; Connor et al., 1989; Sternberg et al.,
1989) it has become clear that a substantial proportion of
tumours that respond to these regimens are ultimately des-
tined to relapse, and that the percentage of patients who are
Table I Results ofrandomised trials ofsingle agent and combination
chemotherapy regimens for advanced bladder cancer.
No. of Response Median Survival First author
Regimen patients rate survival tail ofseries
Cy 59 20% <12.0 <20% Solowaya
CyC 50 12% <12.0 <20%
C 67 17% 6.0 <15%/o Khandekar
CyDC 63 33% 7.3 <15%
C 57 16% 5.0 <10% Troner
CyDC 52 21% 7.0 <10%
C 55 31% 7.2 <20% Hillcoat
MC 53 45% 8.7 <20%
C 110 9% 8.7 <30%? Loehrer
MVDC 110 33% 12.6 <30%?
a35% ofrandomised patients were ineligible; Cy: cyclosphosphamide;
C: cisplatin; M: methotrexate; D: doxorubicin; V: vinblastine.
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potentially cured (20-30 per cent) would be lower than
anticipated.
There has thus been a risk that these regimens would be
abandoned and the search for a new panacea resumed (Con-
nor et al., 1989). However, a recently completed randomised
trial, carried out by investigators in North America and
Australia has set the situation into a more realistic perspec-
tive (Loehrer et al., 1990). We compared outcomes in
patients treated with single agent cisplatin (70 mgm2) and
the so-called MVAC regimen, with the major endpoint being
survival. Although the difference in reported median survival
is only modest (8 vs 12 months), there is a statistically
significant improvement throughout the survival curves when
MVAC is used, but at the expense of a statistically significant
increase in toxicity (Loehrer et al., 1990). It thus appears
that, for the younger and more robust patient, the best
known outcome in metastatic bladder cancer can be achieved
by the use of the MVAC regimen. Whether the CMV
regimen (without doxorubicin, but with a higher dose of
cisplatin) gives comparable results is not yet known as the
appropriate comparative trial has not been effected. How-
ever, Logothetis et al. (1989) have shown that the MVAC
regimen confers a survival benefit over the combination of
cyclophosphamide, doxorubicin and cisplatin.
Of concern, a recent trial has reported that toxicity can be
ameliorated by the replacement of cisplatin and doxorubicin,
respectively, by their less toxic analogues, carboplatin and
epirubicin, without loss of efficacy (Waxman et al., 1989).
However, the small treated sample consisted of a mixture of
locally advanced, relapsed and metastatic tumours, and it is
quite likely that a significant reduction in survival could have
been missed. These data should be regarded with caution
until the appropriate stratified, randomised trial has been
carried out to define whether the patterns of toxicity and
survival are different.
The provocative studies of Gabrilove et al. (1988), in
which the use of colony stimulating factors reduced bone
marrow and mucosal toxicity from the MVAC regimen, has
given rise to new protocols in which the dose of MVAC is
being escalated in the hope of increasing cure rates as a
function of dose intensity. Once again, a randomised trial is
planned to test this hypothesis.
Pre-emptive (neo-adjuvant) chemotherapy
In view of the relatively low cure rate from conventional
treatment of invasive bladder cancer by cystectomy or radio-
therapy (Skinner & Lieskovsky, 1984; Shipley et al., 1984;
Gospodarowicz et al., 1989; Raghavan et al., 1990), attempts
have been made to develop innovative approaches to this
problem. Based upon the high response rates recorded from
the use of systemic chemotherapy for metastatic disease,
several trials have been initiated to assess the efficacy of
first-line chemotherapy as an adjunct to definitive treatment.
The rationale for this approach has been reviewed in detail
elsewhere (Raghavan, 1988).
Initially, a series of phase I and phase II clinical trials
demonstrated that first-line intravenous or intra-arterial
chemotherapy could be administered safely to the elderly
population of patients with bladder cancer, and that few
patients developed clinical evidence of metastases during the
period of chemotherapy (Fagg et al., 1984; Raghavan et al.,
1985; Jakse & Frommhold, 1985; Schulman et al., 1985;
Shipley et al., 1988; Eapen et al., 1989). Although it proved
difficult to assess response in the primary tumour (Raghavan
et al., 1985; Van Oosterom et al., 1986; Scher et al., 1988),
objective response rates of 60-80 per cent were recorded in
most studies (Table II), although it is quite possible that the
available literature was biased by editorial preference for
'positive' results (Simes, 1986). In general, patients tolerated
the chemotherapy programmes with only modest side effects,
and subsequent radiotherapy and/or cystectomy were not
compromised by the use of chemotherapy. Provided that
meticulous attention was paid to hydration schedules and
anti-emetic regimens, even patients aged more than 70 years
could be treated with safety, with sustained objective re-
sponses and with satisfactory quality of life when measured
some years after treatment (Raghavan et al., 1988). However,
from these studies, it was not possible to determine the
optimal approach to this treatment, and questions regarding
dose, sequencing of treatment modalities, and delivery of
cytotoxics (intravenous or intra-arterial) remained unre-
solved.
Moreover, these studies did not address the issue of im-
proved survival, although the published results have
erroneously been compared in some instances with historical
controls. To date, only two randomised, controlled trials
have been completed in which the impact of pre-emptive
chemotherapy on survival has been assessed for patients with
invasive bladder cancer. Shearer et al. (1988) showed no
survival benefit from the use of initial intravenous methotrex-
ate followed by radiotherapy and adjuvant methotrexate,
compared to radiotherapy alone. In parallel studies in Aus-
tralia and the West Midlands, the use of 2-3 doses of
intravenous cisplatin (100 mg m-2) did not appear to in-
fluence survival when radiotherapy was used as the definitive
treatment (Raghavan et al., 1989; Wallace et al. submitted),
Table II Results of clinical trials of pre-emptive chemotherapy for invasive bladder cancer
Response rate qfter Response rate after
chemotherapy all treatment Median
C.R. P.R. R.R. C.R. P.R. R.R. survival Actuarial long
First author Regimen (%) (oo) (%) (%) (%) (%) (months) term survival
Pre-emptive chemotherapy regimens
Fagg C 0 64 64 ? ? ? ? ?
Kaye CyMF 0 0 0 0 0 0 27 26% 3yr
Raghavan C -60- 60 -85- 85 32 40% 5yr
Scher' MVDC 21 39 60 30 57 87b ? ?
Shearer M 56 23 39% 3yr
RT only - 50 20 37% 3yr
Wallace C - -24 39% 3yr
RT only -.22 39% 3yr
Zinckea MVDC 50 19 69 0 0 92 ? ?
Concurrent chemotherapy regimens wvith radiotherapy
Eapen C 92 - 92 ? ?
Rotman F -- - 50 42 92c <30? ?
Shipley C 76 30 30% 3yr,T3
25% 3yr,T4
aCystectomy as definitive treatment; bFigures extrapolated from paper; 4 clinically staged and 5
pathologically staged with residual CA after Rx; CAll T categories; prolonged treatment programme;
relatively short follow up; C.R.: complete remission; P.R.: partial remission; R.R.: total remission rate; Rx:
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although a difference of less than 20 per cent would have
been missed because only 250 patients were randomised.
Regrettably, the trials in the West Midlands and Australia
closed prematurely, owing to lack of patient accrual (based
on biases regarding the utility of the MVAC regimen and the
changing application of cystectomy to the management of
bladder cancer), and the results were analysed by the statis-
tical technique of meta- or overview analysis (Sacks et al.,
1987).
In order to define more clearly the potential benefits ofthis
approach, an international randomised controlled trial has
been initiated, with participation by the Medical Research
Council, European Organisation for Research and Treatment
of Cancer, Australian Bladder Cancer Group, National
Cancer Institute of Canada, Spanish Bladder Cancer Group
and the Finnish National Bladder Cancer Study Group. This
trial will test the survival impact of three cycles of CMV
combination chemotherapy (Meyers et al., 1985) when added
to standard treatment (radiotherapy or cystectomy) for
invasive, clinically non-metastatic bladder cancer. The use of
the CMV regimen is predicated on the higher response rate
documented for combination chemotherapy (Table I), and
the concern that the negative trials of single agent chemo-
therapy may simply reflect inadequate chemotherapy regi-
mens.
After nearly a decade of clinical investigation, the true role
of pre-emptive chemotherapy has not been defined for inva-
sive bladder cancer. There has been a wastage of resources
(patients, cytotoxics and facilities) in the quest for a 'quan-
tum leap forward', with the development of many small,
innovative, but inevaluable pilot studies at the expense of
accrual to well-designed, randomised trials. It is high time for
this issue to be resolved by the completion of a well-struc-
tured trial with adequate accrual of patients, well defined
endpoints and comparison with a conventionally treated con-
trol population. By contrast, the completion of such a trial in
the management of metastatic disease has already defined
more clearly the benefits and limitations of an intensive
schedule of combination chemotherapy and has laid the
foundation for future studies. As our understanding of
mechanisms and predictors of resistance to cytotoxic chemo-
therapy evolves and our approach to the design and applica-
tion of clinical trials improves, the emphasis of our work will
hopefully shift from the empirical to the rational, and the
rate of real progress will accelerate.
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